NCT06291675View on ClinicalTrials.gov

Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

March 3, 2023

Primary Completion Date

March 3, 2027

Study Completion Date

March 3, 2033

Conditions

Gender DysphoriaHormone Therapy Induced Morphologic Change

Interventions

DRUG

gender-affirming hormone therapy

We are not technically involved in the prescription of gender-affirming hormone therapy. We merely aim at observing effects of GAHT on MRI measured organ lipid content, myocardial mass and function.

Trial Locations (1)

1090

RECRUITING

Chiari Stoffwechselambulanz, Medical University of Vienna, Vienna

All Listed Sponsors

lead

Medical University of Vienna

OTHER

NCT06291675 - Gender-Affirming Hormone Therapy and Its Impact on Myocardial Mass and Cardiac Function, Heart, Liver and Pancreatic Fat Content | Biotech Hunter | Biotech Hunter